According to research from the US Health and Human Services, US tax payers pay 1.8 times the international price for medicines, and are 'subsidizing' global healthcare. In order to combat this imbalance, the Trump administration is proposing the “International Pricing Index” (IPI) payment model to reduce reimbursement levels for the Centers for Medicare & Medicaid Services (CMS). This session will present original research modelling the potential impact both short and long term for patients, payers, and industry for such proposals, and show how the IPI can impact access and innovation broadly. As well, our panellists will place the IPI into the context of other models currently being investigated internationally such as value based payments, managed entry agreements, and adaptive pathways.

Session ID: 549972